Ventilator Associated Pneumonia (VAP) R&D Pipeline Analysis Report, Q4 2020
Ventilator Associated Pneumonia (VAP) Pipeline Overview
The Q4 Ventilator Associated Pneumonia (VAP) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Ventilator Associated Pneumonia (VAP), provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Ventilator Associated Pneumonia (VAP) Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Ventilator Associated Pneumonia (VAP) disease overview, Ventilator Associated Pneumonia (VAP) types, Ventilator Associated Pneumonia (VAP) symptoms, causes, and FDA/EMA approved treatment options.
Ventilator Associated Pneumonia (VAP) Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Ventilator Associated Pneumonia (VAP) indication. The report presents near-term and long-term pipeline development trends and potential insights.
Ventilator Associated Pneumonia (VAP) Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 23 companies. Business profiles and contact details of the companies actively perusing Ventilator Associated Pneumonia (VAP) pipeline are assessed.
Ventilator Associated Pneumonia (VAP) R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Ventilator Associated Pneumonia (VAP) discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Ventilator Associated Pneumonia (VAP) companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Ventilator Associated Pneumonia (VAP) pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Ventilator Associated Pneumonia (VAP) Pipeline Market News and Developments during 2020
The Ventilator Associated Pneumonia (VAP) industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Ventilator Associated Pneumonia (VAP) Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
The Q4 Ventilator Associated Pneumonia (VAP) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Ventilator Associated Pneumonia (VAP), provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Ventilator Associated Pneumonia (VAP) Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Ventilator Associated Pneumonia (VAP) disease overview, Ventilator Associated Pneumonia (VAP) types, Ventilator Associated Pneumonia (VAP) symptoms, causes, and FDA/EMA approved treatment options.
Ventilator Associated Pneumonia (VAP) Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Ventilator Associated Pneumonia (VAP) indication. The report presents near-term and long-term pipeline development trends and potential insights.
Ventilator Associated Pneumonia (VAP) Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 23 companies. Business profiles and contact details of the companies actively perusing Ventilator Associated Pneumonia (VAP) pipeline are assessed.
Ventilator Associated Pneumonia (VAP) R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Ventilator Associated Pneumonia (VAP) discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Ventilator Associated Pneumonia (VAP) companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Ventilator Associated Pneumonia (VAP) pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Ventilator Associated Pneumonia (VAP) Pipeline Market News and Developments during 2020
The Ventilator Associated Pneumonia (VAP) industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Ventilator Associated Pneumonia (VAP) Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
- Ventilator Associated Pneumonia (VAP) pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates
- Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.
- Company-company partnerships, company-institute partnerships, and investment details of companies are included
- 23 companies are included including Antabio SAS, Aridis Pharmaceuticals Inc, AstraZeneca Plc, Bioversys AG, Cumberland Pharmaceuticals Inc, CytaCoat AB, Destiny Pharma Ltd, Dong-A Socio Holdings Co Ltd, EnBiotix Inc, Helperby Therapeutics Group Ltd, Meiji Seika Pharma Co Ltd, Merck & Co Inc, Motif Bio Plc, Nabriva Therapeutics plc, Nosopharm SAS, Peptineo, Pulmobiotics SL, Qilu Pharmaceutical Co Ltd, Shionogi & Co Ltd, Spero Therapeutics Inc, TGV-Inhalonix Inc, VenatoRx Pharmaceuticals Inc, Wockhardt Ltd,
- Disease overview, Pipeline trends, market analysis, and other developments
- Potential licensing/new business opportunities in Ventilator Associated Pneumonia (VAP) pipeline market
- Global coverage of companies and pipeline agents
- 2020 Trends, market analysis, and developments
- Potential growth opportunities
- Comprehensive details of drug candidates
- Drive pipeline research and commercial assessment
- Assess most promising drug candidates and stay ahead of the competition
- Strengthen your pipeline through identifying business expansion and acquisition opportunities
- Develop new candidates based on most focused targets and mechanism of actions
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. VENTILATOR ASSOCIATED PNEUMONIA (VAP) PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Ventilator Associated Pneumonia (VAP) Pipeline, 2020
2.2 Most focused Mechanism of Action in Ventilator Associated Pneumonia (VAP) Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Ventilator Associated Pneumonia (VAP) pipeline
2.5 Active Companies Developing Ventilator Associated Pneumonia (VAP) pipeline
3. VENTILATOR ASSOCIATED PNEUMONIA (VAP) DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. VENTILATOR ASSOCIATED PNEUMONIA (VAP) PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 Antabio SAS
Aridis Pharmaceuticals Inc
AstraZeneca Plc
Bioversys AG
Cumberland Pharmaceuticals Inc
CytaCoat AB
Destiny Pharma Ltd
Dong-A Socio Holdings Co Ltd
EnBiotix Inc
Helperby Therapeutics Group Ltd
Meiji Seika Pharma Co Ltd
Merck & Co Inc
Motif Bio Plc
Nabriva Therapeutics plc
Nosopharm SAS
Peptineo
Pulmobiotics SL
Qilu Pharmaceutical Co Ltd
Shionogi & Co Ltd
Spero Therapeutics Inc
TGV-Inhalonix Inc
VenatoRx Pharmaceuticals Inc
Wockhardt Ltd
5. VENTILATOR ASSOCIATED PNEUMONIA (VAP) PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. VENTILATOR ASSOCIATED PNEUMONIA (VAP) PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2. VENTILATOR ASSOCIATED PNEUMONIA (VAP) PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Ventilator Associated Pneumonia (VAP) Pipeline, 2020
2.2 Most focused Mechanism of Action in Ventilator Associated Pneumonia (VAP) Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Ventilator Associated Pneumonia (VAP) pipeline
2.5 Active Companies Developing Ventilator Associated Pneumonia (VAP) pipeline
3. VENTILATOR ASSOCIATED PNEUMONIA (VAP) DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. VENTILATOR ASSOCIATED PNEUMONIA (VAP) PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 Antabio SAS
Aridis Pharmaceuticals Inc
AstraZeneca Plc
Bioversys AG
Cumberland Pharmaceuticals Inc
CytaCoat AB
Destiny Pharma Ltd
Dong-A Socio Holdings Co Ltd
EnBiotix Inc
Helperby Therapeutics Group Ltd
Meiji Seika Pharma Co Ltd
Merck & Co Inc
Motif Bio Plc
Nabriva Therapeutics plc
Nosopharm SAS
Peptineo
Pulmobiotics SL
Qilu Pharmaceutical Co Ltd
Shionogi & Co Ltd
Spero Therapeutics Inc
TGV-Inhalonix Inc
VenatoRx Pharmaceuticals Inc
Wockhardt Ltd
5. VENTILATOR ASSOCIATED PNEUMONIA (VAP) PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. VENTILATOR ASSOCIATED PNEUMONIA (VAP) PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
